In this study, treatment with merestinib, a MET-targeting kinase inhibitor, at the once daily dose of 12 mg/kg resulted in durable tumor regression in mice bearing Hs746t xenograft tumors with MET exon14 skipping and MET amplification. The gene discussed is MET; the disease is neoplasm.